Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 9,514 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive

NCT00264537
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo injections, Placebo capsules, Methotrexate capsules, Golimumab 50 mg injections, Golimumab 100 mg injections
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 20, 2026, 10:16 PM EDT
Recruiting Phase 4 Interventional

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

NCT06581328
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 10:16 PM EDT
Completed No phase listed Observational

Colpocleisis for Advanced Pelvic Organ Prolapse

NCT00271037
View directory record Official record
Conditions
Pelvic Organ Prolapse, Stress Urinary Incontinence
Interventions
Colpocleisis prolapse repair surgery, sling or other to treat or prevent stress incontinence
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Maywood, Illinois • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

NCT00569972
View directory record Official record
Conditions
Insomnia
Interventions
PD 0200390, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 20, 2026, 10:16 PM EDT
Terminated Phase 2 Interventional

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

NCT00058981
View directory record Official record
Conditions
Diabetes, Autoimmune
Interventions
DiaPep277
Drug
Lead sponsor
DeveloGen Israel, Ltd.
Industry
Eligibility
30 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
7
States / cities
Birmingham, Alabama • Aurora, Colorado • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2009 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Efficacy and Mechanisms of a Novel Intervention for Chronic Pain Tailored to People Living With HIV

NCT03692611
View directory record Official record
Conditions
Chronic Pain
Interventions
Skills TO Manage Pain (STOMP), Comparison group
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 89 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 2 Interventional

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

NCT01904409
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Placebo, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet, Rifaximin SSD 80 mg SER tablet, Rifaximin SSD 80mgIR/80mgSER tablet
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
113
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 20, 2026, 10:16 PM EDT
Recruiting Phase 1 Interventional

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

NCT05272384
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Duarte, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional

Mindfulness-Based Diabetes Education for Adults With Elevated Diabetes Distress

NCT05195138
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mindfulness-Based Diabetes Education, Standard Diabetes Self-Management Education (DSME)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

NCT02403271
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
Interventions
Ibrutinib, Durvalumab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional Results available

Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)

NCT03540771
View directory record Official record
Conditions
End Stage Liver Disease, Decompensated Cirrhosis of Liver
Interventions
Palliative Care
Other
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 120 Years
Enrollment
1,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01493687
View directory record Official record
Conditions
Papulopustular Rosacea (PPR)
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

NCT00457821
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor 25 mg/75 mg, Ivacaftor 75 mg/150 mg, Ivacaftor 150 mg or 250 mg, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 20, 2026, 10:16 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

NCT02785952
View directory record Official record
Conditions
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1201
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 20, 2026, 10:16 PM EDT
Terminated Phase 4 Interventional

Plasma Resuscitation Without Lung Injury

NCT04681638
View directory record Official record
Conditions
Burns
Interventions
Pathogen-Reduced Plasma, Crystalloid Solutions
Drug
Lead sponsor
Coalition for National Trauma Research
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional

An Alternative Treatment for Cervical Intraepithelial Neoplasia Using the Focal Loop Electrosurgical Excision Procedure

NCT02220192
View directory record Official record
Conditions
High-grade Cervical Intraepithelial Neoplasia
Interventions
Focal LEEP
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 3 Interventional Results available

Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)

NCT00147199
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Inhaled treprostinil, Placebo inhalation solution
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional Results available

A Prospective Study Evaluating the Performance of Nanotite Osseotite Implants When Placed by Graduate Student Programs

NCT00726063
View directory record Official record
Conditions
Tooth Disease, Partial Edentulism
Interventions
Nanotite dental implant, Osseotite dental implant
Device
Lead sponsor
ZimVie
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 20, 2026, 10:16 PM EDT
Terminated No phase listed Observational Results available

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

NCT02292706
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Ribavirin, LDV/SOF, SOF/VEL, SOF/VEL/VOX, Other SOF-Based Regimen, Ineligible parent treatment
Drug · Other
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 3 Interventional

Open Label Extension Study of PREOS

NCT00172133
View directory record Official record
Conditions
Osteoporosis
Interventions
ALX1-11 (drug)
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
84
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Phase 4 Interventional Results available

FS-67 in the Treatment of Pediatric Patients With Ankle Sprain

NCT01037816
View directory record Official record
Conditions
Ankle Sprain
Interventions
FS-67 Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 20, 2026, 10:16 PM EDT
Completed Not applicable Interventional Results available

Impact of Heart Rate Characteristics Monitoring in Neonates

NCT00307333
View directory record Official record
Conditions
Sepsis
Interventions
HeRO heart rate characteristics monitor
Device
Lead sponsor
University of Virginia
Other
Eligibility
1 Day to 32 Weeks
Enrollment
3,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • Miami, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 20, 2026, 10:16 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

NCT06544733
View directory record Official record
Conditions
HIV-1-Infection
Interventions
Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
35
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 20, 2026, 10:16 PM EDT
Not listed No phase listed Observational

Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry

NCT02907398
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Inspire therapy, No intervention
Device · Other
Lead sponsor
Inspire Medical Systems, Inc.
Industry
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
53
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 20, 2026, 10:16 PM EDT